Study #2024-0023
A randomized, double-blind, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic non-small cell lung cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Ivonescimab Injection, Pembrolizumab Injection
Description
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-Small Cell Lung Cancer
Study phase:
Phase III
Physician name:
Jianjun Zhang
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-934-6089
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.